107 related articles for article (PubMed ID: 30736285)
1. Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases.
Mansinho A; Ferreira AR; Casimiro S; Alho I; Vendrell I; Costa AL; Sousa R; Abreu C; Pulido C; Macedo D; Pacheco TR; Correia L; Costa L
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736285
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
[TBL] [Abstract][Full Text] [Related]
3. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
4. FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study.
Desbiens LC; Sidibé A; Ung RV; Fortier C; Munger M; Wang YP; Bisson SK; Marquis K; Agharazii M; Mac-Way F
Osteoporos Int; 2018 Oct; 29(10):2345-2353. PubMed ID: 29959497
[TBL] [Abstract][Full Text] [Related]
5. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
[TBL] [Abstract][Full Text] [Related]
6. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?
Lee EK; Martinez MC; Blakely K; Santos KD; Hoang VC; Chow A; Emmenegger U
Med Hypotheses; 2014 Oct; 83(4):482-7. PubMed ID: 25155552
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D.
Zhang M; Yan J; Zhu M; Ni Z
Ann Clin Lab Sci; 2015; 45(1):17-22. PubMed ID: 25696005
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
9. Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors.
Kim SH; Kim JW; Hwang IG; Jang JS; Hong S; Kim TY; Baek JY; Shin SH; Sun S; Hong DS; Kim HJ; Hong YS; Woo IS; Lee JH; Kim JH
J Geriatr Oncol; 2019 Sep; 10(5):749-756. PubMed ID: 30952517
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.
Ter Maaten JM; Voors AA; Damman K; van der Meer P; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Navis G; Ng L; Ouwerkerk W; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; de Borst MH
Int J Cardiol; 2018 Feb; 253():84-90. PubMed ID: 29306478
[TBL] [Abstract][Full Text] [Related]
11. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
12. Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study.
Haring R; Enserro D; Xanthakis V; Mitchell GF; Benjamin EJ; Hamburg NM; Sullivan L; Nauck M; Wallaschofski H; Vasan RS
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27385427
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
Hsu HJ; Wu MS
Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
[TBL] [Abstract][Full Text] [Related]
14. Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.
Tsuda Y; Nakagawa T; Shinoda Y; Kanatani A; Kawai T; Taguchi S; Yamada Y; Sawada R; Kume H; Homma Y; Tanaka S; Kawano H
Int J Clin Oncol; 2017 Jun; 22(3):548-553. PubMed ID: 28044212
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Lyngbakken MN; Pervez MO; Brynildsen J; Pedersen MH; Sølvernes J; Christensen G; Høiseth AD; Omland T; Røsjø H
Clin Biochem; 2018 Feb; 52():41-47. PubMed ID: 29074091
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
17. Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial.
de Borst MH; Baia LC; Hoogeveen EK; Giltay EJ; Navis G; Bakker SJL; Geleijnse JM; Kromhout D; Soedamah-Muthu SS
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29137111
[TBL] [Abstract][Full Text] [Related]
18. The Association between Fever and Prognosis in Lung Cancer Patients with Bone Metastases Receiving Zoledronic Acid.
Sunaga T; Shimamoto K; Nakamura S; Takahashi N; Higashino M; Hozumi T; Matsui M; Nagatani A; Kokubu F; Kogo M; Sasaki T
Chemotherapy; 2017; 62(6):327-333. PubMed ID: 28605733
[TBL] [Abstract][Full Text] [Related]
19. Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study.
di Giuseppe R; Kühn T; Hirche F; Buijsse B; Dierkes J; Fritsche A; Kaaks R; Boeing H; Stangl GI; Weikert C
PLoS One; 2015; 10(7):e0133580. PubMed ID: 26193703
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
Cancela AL; Oliveira RB; Graciolli FG; dos Reis LM; Barreto F; Barreto DV; Cuppari L; Jorgetti V; Carvalho AB; Canziani ME; Moysés RM
Nephron Clin Pract; 2011; 117(1):c74-82. PubMed ID: 20689328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
